VXRT News and Press, Vaxart Inc. From 01/21/21

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020. These companies on average are unprofitable and tra...

Vaxart (VXRT) may have seen over a thirteen-fold rise in share price over the past 12-month period thanks to its COVID-19 vaccine development. That meteoric rise has not discouraged the analysts to issue bullish views on the stock despite two COVID-19 vaccine candidates receiving conditional ...

Multiple biotechs have coronavirus vaccines with regulatory authorizations, and others are about to cross the finish line . But investors should still keep an eye on the early-stage companies, such as Inovio (NASDAQ: INO) and Vaxart (NASDAQ: VXRT) . In this video from ...

Vaxart (NASDAQ: VXRT) had an amazing run in 2020. The tiny biotech started off the year as a micro-cap stock, but when the COVID-19 pandemic struck, it -- like many vaccine-related stocks -- took off. Vaxart jumped out of obscurity and delivered one of the market's top performances ...

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) will almost certainly enjoy huge revenue growth this year. Their respective coronavirus vaccines have already been given to millions of people in the U.S. and other countries. Billions of dollars will soon flow into the drugmaker...

Vaxart (NASDAQ: VXRT) isn't as well-known as other coronavirus vaccine makers. However, the small biotech stock emerged as a huge winner in 2020. Vaxart is currently evaluating its tablet COVID-19 vaccine in an early stage clinical study. In this Motley Fool Live video recorded ...

While much of the discussion around COVID-19 vaccines has lately focused on the difficulties of shipping and storing them at temperatures that would make a polar bear shiver, Vaxart (NASDAQ: VXRT) has been steadily working on developing one that would eliminate a lot of the logistic...

This article reviews the Value & Momentum Breakouts 2020 trading year and addresses new strategies, models, and enhancements for 2021. 10 different model portfolios beat the S&P 500 in 2020 and six of these methods have beaten the S&P 500 consistently the past several year...

How did your investments perform in 2020? Hopefully, quite well. Last year turned out to be an easy one for investors to make money. The S&P 500 index jumped 16%. If you bought stocks during the market meltdown in March or shortly afterward, you could have enjoyed exceptionally ...

Moderna and Pfizer were first to market with their coronavirus vaccines. The U.S. Food and Drug Administration (FDA) granted them both Emergency Use Authorization (EUA) last month. But that doesn't mean the vaccine race is over. Considering global demand, there is plenty of room for...